摘要
索利那新是一种新的选择性毒蕈碱M_3受体拮抗药,能选择性抑制膀胱节律性收缩而不影响唾液的分泌,临床用于治疗有尿急、尿频症状的膀胱过度活动症。索利那新对膀胱毒蕈碱M_3受体具有高度特异性和选择性,其吸收不受食物影响,生物利用度高,分布迅速,经肝脏代谢,主要通过肾脏排泄,老年患者无需调整剂量。索利那新治疗膀胱过度活动症临床疗效显著,不良反应较少。
Solifenacin is a new selective M3 receptor antagonist, capable of inhibiting selectively bladder rhythmic contraction without affecting the secretion of saliva, clinically for the treatment of overactive bladder with urinary urgency, urinary frequency, and so on. Solifenacin has a high degree of specificity and selectivity for M3 receptor bladder. The absorption of solifenacin was not affected by food, and it has high degree of bioavailability and rapidly distributed. Solifenacin was metabolized by the liver and primarily by renal excretion.Older patients needn＇ t dose adjustment. Solifenacin is effective in treatment of overactive bladder, with less adverse reactions.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2013年第10期771-774,共4页
Chinese Journal of New Drugs and Clinical Remedies
关键词
索利那新
膀胱
过度活动性
毒蕈碱拮抗剂
solifenacin
urinary bladder, overactive
muscarinic antagonist
